Trials / Completed
CompletedNCT00170781
Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout
A 1-Week, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Parallel Trial Comparing Lumiracoxib (400 mg Once Daily) in Patients With Acute Flares of Gout, Using Indomethacin (50 mg Three Times a Day)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 234 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to develop our understanding of the efficacy and safety of using lumiracoxib in the treatment of patients with acute gout. This is a multi-center, double-blind, randomized, parallel group study comparing a single daily dose of 400 mg lumiracoxib with the established dose of indomethacin 50 mg taken three times a day in terms of efficacy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lumiracoxib |
Timeline
- Start date
- 2005-06-01
- First posted
- 2005-09-15
- Last updated
- 2006-11-30
Locations
2 sites across 2 countries: Germany, Switzerland
Source: ClinicalTrials.gov record NCT00170781. Inclusion in this directory is not an endorsement.